JPWO2020201038A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020201038A5 JPWO2020201038A5 JP2021557778A JP2021557778A JPWO2020201038A5 JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5
- Authority
- JP
- Japan
- Prior art keywords
- lipocalin mutein
- lipocalin
- medicament according
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000019298 Lipocalin Human genes 0.000 claims description 93
- 108050006654 Lipocalin Proteins 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 210000002345 respiratory system Anatomy 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 230000009285 allergic inflammation Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 102000047202 human LCN2 Human genes 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826767P | 2019-03-29 | 2019-03-29 | |
| US62/826,767 | 2019-03-29 | ||
| EP19166435.8 | 2019-04-01 | ||
| EP19166435 | 2019-04-01 | ||
| EP19175818.4 | 2019-05-22 | ||
| EP19175818 | 2019-05-22 | ||
| EP19177568.3 | 2019-05-31 | ||
| EP19177568 | 2019-05-31 | ||
| EP19211404.9 | 2019-11-26 | ||
| EP19211404 | 2019-11-26 | ||
| PCT/EP2020/058637 WO2020201038A1 (en) | 2019-03-29 | 2020-03-27 | Inhaled administration of lipocalin muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526367A JP2022526367A (ja) | 2022-05-24 |
| JPWO2020201038A5 true JPWO2020201038A5 (enrdf_load_stackoverflow) | 2023-04-03 |
Family
ID=70292935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557778A Withdrawn JP2022526367A (ja) | 2019-03-29 | 2020-03-27 | リポカリンムテインの吸入投与 |
Country Status (8)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR124436A1 (es) * | 2020-12-18 | 2023-03-29 | Astrazeneca Ab | Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7892827B2 (en) * | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| MX2009001203A (es) | 2006-08-01 | 2009-06-01 | Pieris Ag | Muteinas de lipocalina lacrimosa y metodos para obtener las mismas. |
| CA2713557C (en) * | 2008-01-30 | 2016-06-07 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| CN102770764B (zh) * | 2009-12-07 | 2016-04-20 | 皮里斯股份公司 | 对给定靶标具有亲和力的人脂质运载蛋白2（Lcn2，hNGAL）的突变蛋白 |
| LT2580236T (lt) * | 2010-06-08 | 2019-06-25 | Pieris Pharmaceuticals Gmbh | Ašarų lipokalino muteinai, surišantys il-4 r alfa |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| US9260492B2 (en) * | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| WO2012072806A1 (en) | 2010-12-02 | 2012-06-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for ctla-4 |
| CA2858959A1 (en) | 2011-12-12 | 2013-06-20 | Pieris Ag | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| CA2858962C (en) * | 2011-12-13 | 2023-09-05 | Pieris Ag | Compositions of human tear lipocalin muteins and methods of use thereof |
| CA2860843C (en) * | 2012-01-09 | 2021-03-23 | Pieris Ag | Methods for preventing, treating or diagnosing disorders |
| WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| US10526384B2 (en) * | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| EP2968490A1 (en) * | 2013-03-14 | 2016-01-20 | Daiichi Sankyo Co., Ltd. | Novel binding proteins for pcsk9 |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RU2723034C2 (ru) * | 2014-05-22 | 2020-06-08 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые полипептиды со специфическим связыванием и пути их применения |
| EP3250586B1 (en) * | 2015-01-28 | 2021-10-27 | Pieris Pharmaceuticals GmbH | Novel proteins specific for angiogenesis |
| CA2976687A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| CA2980840A1 (en) * | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| DK3292137T3 (da) * | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| LT3298030T (lt) * | 2015-05-18 | 2023-02-27 | Pieris Pharmaceuticals Gmbh | Sulietas polipeptidas prieš vėžį |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| EP3115371A1 (en) * | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| KR20180029238A (ko) | 2015-07-15 | 2018-03-20 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 특이적인 신규 단백질 |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| MX2019008434A (es) * | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina con afinidad de unión por lag-3. |
| AU2019315703A1 (en) * | 2018-07-31 | 2020-12-10 | Les Laboratoires Servier | Novel fusion protein specific for CD137 and PD-L1 |
| EP3843849A1 (en) * | 2018-08-27 | 2021-07-07 | Pieris Pharmaceuticals GmbH | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
| CA3124441A1 (en) * | 2019-02-26 | 2020-09-03 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| CA3133422A1 (en) * | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| EP4161957A1 (en) * | 2020-06-05 | 2023-04-12 | Pieris Pharmaceuticals GmbH | Multimeric immunomodulator targeting 4-1bb |
| US20230366884A1 (en) * | 2020-09-18 | 2023-11-16 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
-
2020
- 2020-03-27 WO PCT/EP2020/058637 patent/WO2020201038A1/en unknown
- 2020-03-27 JP JP2021557778A patent/JP2022526367A/ja not_active Withdrawn
- 2020-03-27 KR KR1020217035440A patent/KR20210146999A/ko not_active Withdrawn
- 2020-03-27 AU AU2020253034A patent/AU2020253034A1/en not_active Abandoned
- 2020-03-27 CA CA3127973A patent/CA3127973A1/en active Pending
- 2020-03-27 US US17/599,765 patent/US20220168387A1/en not_active Abandoned
- 2020-03-27 CN CN202080025546.6A patent/CN113939307A/zh active Pending
- 2020-03-27 EP EP20719569.4A patent/EP3946417A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| US10596146B2 (en) | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders | |
| ES2780127T3 (es) | Formulación superfina de formoterol | |
| JP2025037885A (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| JP2023086774A (ja) | 乾燥粉末配合および使用方法 | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| KR20100091970A (ko) | 파킨슨병 치료용 조성물 | |
| JPH0648958A (ja) | 吸入による非ステロイド系抗炎症剤の抗反応抗喘息活性 | |
| EP2346509A1 (en) | Inhalation of levofloxacin for reducing lung inflammation | |
| WO2017027387A1 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| EP3484458A1 (en) | Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces | |
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| WO2021212183A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| Beck-Broichsitter et al. | Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension | |
| IT202000005026A1 (it) | Lattoferrina per uso inalatorio ad azione antivirale | |
| Jin et al. | RETRACTED: Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases | |
| Sheikh et al. | Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment? | |
| CN106667974A (zh) | 一种吸入用硫酸特布他林溶液制备方法 | |
| JP2023551989A (ja) | 生成物送達デバイス及び方法 | |
| CN118806738A (zh) | 一种吸入施用的药物制剂及其在医药上的应用 | |
| JP2019516797A5 (enrdf_load_stackoverflow) | ||
| JPWO2020201038A5 (enrdf_load_stackoverflow) | ||
| CN110505873B (zh) | 鼻内肾上腺素制剂及治疗疾病的方法 | |
| WO2001015777A1 (en) | Pulmonary-administration of mineral ascorbates |